Pancreatic cancer is one of the leading cancer type that results in mortality. The mainstay of treatment for metastatic pancreatic cancer is chemotherapy. Entrectinib is a new inhibitor for TRK and ROS1 that has shown clinical activity in lung cancer treatment. At the 2018 Gastrointestinal Cancers Symposium, a study showed clinical benefit of entrectinib in treating metastatic pancreatic cancer with NTRK and ROS1 fusion. Two metastatic pancreatic cancer patients with TPR-NTRK gene fusion and one with an SCL-ROS1 gene fusion were treated with entrectinib at 600 mg daily. The two patients with TPR-NTRK gene fusion had partial response and the patient with SCL-ROS1 gene fusion had stable disease for at least 6 months. Entrectinib was well tolerated on the study. These results reveal that entrectinib may be a potential targeted therapy for metastatic pancreatic cancer.
Pishvaian MJ, Rolfo CD, Lie SV, et al. J Clin Oncol. 2018;36 (suppl 4S;abstr 521).